Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trialYunpeng Yang, Li Zhang, Jianya Zhou et al.|The Lancet Respiratory Medicine|2019Cited by 139
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA SequencingYunpeng Yang, Li Zhang, Jianhua Chen et al.|Journal of Thoracic Oncology|2021Cited by 44
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)Xinan Sheng, Dingwei Ye, Aiping Zhou et al.|European Journal of Cancer|2022Cited by 20
Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib studyXingsheng Hu, Yuankai Shi, Ziping Wang et al.|BMC Cancer|2023Cited by 8